Abstract
INTRODUCTION
Hepatitis C virus (HCV) infection is a major worldwide health problem. It is one of the most common bloodborne infections in the United States with an estimated 2.7 million people chronically infected in the United States [1] . HCV is also one of the leading causes of cirrhosis and liver transplantation [1, 2] . There are increasing reports indicating an association between HCV and type 2 diabetes mellitus (T2DM). Individuals with HCV are more likely to have risk factors to develop T2DM and patients with T2DM have at least a 2-fold greater risk of developing HCV infection than the general population [3, 4] . Prior studies have shown that chronic HCV infection is associated with a greater risk for the development of insulin resistance [5] . In a retrospective analysis of cirrhotic patients, those with HCV infection were 10 times more likely to have T2DM than those without HCV infection [5] . There is evidence that patients with chronic HCV infection and increased insulin resistance have a higher prevalence of hepatic fibrosis, hepatocellular carcinoma, and other extrahepatic manifestations [6] [7] [8] [9] . While there are unclear mechanisms for increased insulin resistance among those with HCV, factors such as metabolic syndrome, increased hepatic iron, and serum tumor necrosis factor-α have been implicated [10, 11] . Molecular studies have also shown that the mechanism of insulin resistance can differ by HCV genotype. In particular, HCV genotype 3 has been shown to be an independent risk factor for hepatic steatosis and its viral proteins can directly interfere with intracellular insulin signaling [12] . Previously standard therapy for HCV required the use of pegylated interferon-α (P-IFN) and ribavirin. However, these regimens had low sustained virologic response (SVR) rates and were poorly tolerated. During the era of P-IFN therapy, several studies showed that the presence of obesity and/or steatosis led to a reduction of SVR rate in HCV patients [13, 14] . In patients with diabetes and HCV who were treated with IFN-based therapies, HCV clearance was associated with improved insulin resistance and beta cell function [15] . In 2013 and 2014, approval of newer direct acting antiviral agents (DAA) created IFN-free regimens with SVR rates greater than 90%, radically changing HCV treatment. Due to the novelty of DAA regimen, research is being actively pursued in a variety of patient populations. Within the Veterans Health Administration (VA), the incidence of chronic HCV is 2-3 times higher than the general public [16] . Additionally, patients that receive care in the tment with DAA.
Predictor variables
Data extraction included patient demographic, comorbidity, laboratory, and medication data from CPRS. Demographic data included age, sex, BMI, race, and ethnicity. For race and ethnicity, we used one mutuallyexclusive variable that combined concepts of race and ethnicity by including Hispanic as a primary race (nonHispanic white, non-Hispanic black, Hispanic, Asian, other). Comorbidities included the presence of cirrhosis by chart review, elevated Fibrosis-4 (Fib-4) score (a measure of advanced fibrosis), hyperlipidemia (HLD), hypertension (HTN), HIV, and metabolic syndrome as identified by ICD9/ICD10 codes or by chart review. A cutoff value of 3.25 was used to determine a significant Fib-4 score as consistent with prior studies [22] . Within the cohort of patients with both HCV and T2DM, the presence of cirrhosis, ascites, and hepatic encephalopathy were confirmed by chart review of the patient's hepatology notes. If a patient had cirrhosis, clinical laboratory values were used to calculate a patient's Child-Turcotte-Pugh score and Child-TurcottePugh class (CTP). Using a modified World Health Organization definition for metabolic syndrome, we de fined metabolic syndrome as having at least diabetes mellitus and at least two of the following baseline characteristics as determined by ICD-9 CM codes, ICD-10 CM codes, or by medication review: A BMI ≥ 30 kg/m 2 , HTN, and HLD [23] . The presence of HLD was used as a surrogate for elevated triglyceride or reduced HDL cholesterol as we were unable to accurately obtain triglyceride or HDL levels for all patients before statin therapy. Furthermore, because many patients did not have urine albumin or urine creatine measurements, the presence of microalbuminuria was not analyzed. We also documented serological virologic clearance at 12-wk post treatment (SVR12), HCV genotype, and prior HCV treatment for all patients.
Statistical analysis
We performed proportions to summarize demographic and clinical characteristics and used χ 2 tests to examine differences between patients that did achieve SVR12 and those that did not. Medians were compared using the Wilcoxon rank-sum test, and means were compared using analysis of variance (ANOVA). All means are expressed with their respective standard error.
To determine predictors of SVR12, a multivariable logistic regression was performed. Due to the rare event of DAA failure, to examine the relationship between SVR12 and HbA1c, we performed univariable and multivariable penalized maximum likelihood logistic regression analyses similar to prior studies [24, 25] . Predictors included age, sex, race/ethnicity, HCV genotype, treatment experienced or naïve, DAA used, and comorbid conditions (HTN, DM, HLD, HIV, elevated Fib-4, obesity, metabolic syndrome). The reference VA also have a higher prevalence of obesity and T2DM compared to the general population [17, 18] . Thus, the VA presents an ideal population to evaluate the relationship between HCV and T2DM. We aim to determine if successful treatment with DAA is associated with improvements in hemoglobin A1c (HbA1c) and if the presence of T2DM or metabolic syndrome affects SVR rates. 250.00-250.93, ICD-10: E08-E13). Patients with HCV were also included if they had diabetic medications on their medication list during the study period. Patients were excluded from the cohort if they did not have SVR12 data or HbA1c one year after completion of DAA therapy. In addition to the CDW query, we manually extracted patient clinical and demographic data as well as confirm the diagnosis of T2DM from the VA electronic medical records, the Computerized Patient Record System (CPRS), of all patients screened to have both HCV and T2DM by ICD-9 CM or ICD-10 CM codes.
MATERIALS AND METHODS

Study population and data collection
Outcome variables
The primary outcome was the change in HbA1c before and after DAA treatment. The secondary outcomes of interest were change in body mass index (BMI) over the same time period and if the presence of T2DM or other traits of metabolic syndrome such as hyperlipidemia (HDL), hypertension (HTN), or obesity affected SVR12. Serial BMI and HbA1c values were obtained from the year before and the year after HCV treatment and summarized as one-year pre-treatment and one-year posttreatment averages, respectively. A significant change of HbA1c was defined as a difference of 0.5 or greater, consistent with prior similar studies [19, 20] . Through chart review, we also documented whether a patient had an increase or decrease in oral hypoglycemic dose and/or injectable insulin dose from one year before to one year after treatment with DAA. A change of greater than 10% from baseline was considered a significant change in medication, similar to prior studies [21] . Daily insulin was calculated as a total amount of basal and/or meal-time insulin over a 24-h period as documented in the patient's medication list. We also documented if there was a change in the overall number of diabetes medications from one year before to one year after trea-group was female, white, treatment experienced, low Fib-4, without HTN/HLD/metabolic syndrome, genotype 1a, and treated with sofosbuvir/simeprevir. In addition to this model, we performed sub-analyses to determine associations between SVR12 and change in insulin dose required before and after DAA therapy. Statistical assistance was provided by the Institute for Digital Research and Education at UCLA. This study along with a waiver of informed consent was approved by the VA Institutional Review Board and the Research and Development Committee at VAGLAHS.
RESULTS
Cohort characteristics
A total of 1068 patients met inclusion criteria. Baseline characteristics are summarized in Table 1 . In all patients treated with DAA, SVR12 rates differ by age, Fib-4 score, HCV genotype, DAA therapy, and DAA planned duration of treatment. Patients who achieved SVR12 were older (62.0 years vs 60.7 years, P = 0.02). Patients with a Fib-4 score < 3.25 had an SVR12 rate of 90.9% as compared to 80.2% for patients with a Fib-4 score ≥ 3.25. SVR12 rates were varied by HCV genotype, with genotype 2 and 3 having lower SVR12 rates than genotype 1 (P < 0.01). SVR12 rates also were varied by treatment and duration of therapy. SVR12 rates were highest for patients treated with shorter duration (8 and 12 wk as compared to 16 and 24 wk) and with sofosbuvir/ledipasvir (93.7%) as compared to other regimens.
Of the 1068 patients treated with DAA, 106 patients concomitantly had T2DM and HCV and at least one HbA1c value 1-year post SVR12 ( Table 2 ). The average age was 63.2 years (0.5). Within the cohort, 105 (99.1%) were male, 29 (27.4%) were white, 39 (36.8%) were African-American, and 27 (25.5%) were Hispanic. A total of 98 patients (92.5%) achieved SVR12 and 8 patients (7.5%) did not achieve SVR12. Fiftyseven patients (53.8%) had cirrhosis with a majority (82.5%) being compensated (i.e., CTP A). Seventy-two patients (67.9%) were treatment-naïve while 34 patients (32.1%) had been treated with pegylated-interferon in the past. The majority of patients had genotype 1a (n = 60, 56.6%) or 1b (n = 24, 22.6%) disease. Only 16 patients (15.1%) had a normal BMI at the time of treatment (≥ 18 and < 25) while the rest had a BMI ≥ 25. Only 3 patients (2.8%) were co-infected with HIV. Ninetyfive patients (89.6%) had HTN, 79 (74.5%) had HLD, and 85 (80.2%) had metabolic syndrome.
The average age for patients who achieved SVR12 was higher than those who did not (63.5 years vs 59.6 years, respectively, P = 0.04). There were no significant differences between patients who achieved SVR12 and those who did not in regards to sex, race/ethnicity, presence of cirrhosis, prior treatment experience, HCV genotype, treatment regimen, BMI, HIV status, HTN, HLD, or metabolic syndrome (Table 2) .
Changes in HbA1c and BMI
Overall, average HbA1c was significantly lower after DAA therapy: 7.44% vs 6.71%, P = 0.01. For the subgroup of patients that achieved SVR12, the average HbA1c before treatment was significantly higher than the average after treatment (7.35% vs 6.55%, P < 0.01). When SVR12 was not achieved, however, HbA1c was not significantly different before and after treatment: 8.60% vs 8.61%, P = 0.99 (Table 3) . This relationship was preserved across all genotypes with the greatest difference occurring in genotype 3 (Table  3 ). However, there was no difference in the change of HbA1c between genotypes or treatment regimens (Table  4) .
Forty-six patients were on insulin before treatment and 43 patients were on insulin after treatment. Of those patients who were on insulin, the average daily insulin requirement before treatment was 55.1 IU (5.7) and 49.7 IU (6.2) after treatment (P = 0.50). For patients on insulin who achieved SVR12, the average daily insulin requirement before treatment was 55.0 IU (5.85) and the average daily insulin requirement after treatment was 48.2 IU (6.30) (P = 0.42). Insulin requirement also did not change significantly for pat ients who did not achieve SVR12 [55. 
SVR12 is not affected by the components of metabolic syndrome
After adjusting for age, sex, race/ethnicity, cirrhosis, treatment experience, HCV genotype, treatment regimen, HIV status, and treatment duration, the individual components of metabolic syndrome (obesity, HTN, HLD, and T2DM) and the presence of metabolic syndrome itself did not predict SVR12 (Table 5 ). For the full logistic regression for SVR12, please see supplemental Table 1 . 
SVR12 as a predictor of improved insulin resistance
DISCUSSION
This study demonstrates that HCV clearance with DAAs is associated with a clinically significant decrease in HbA1c independent of other demographic and clinical factors such as metabolic syndrome and BMI. This data corroborates recent studies that showed similar outcomes with DAA therapy [26] . While Hum et al [26] attempted to control for DM medication use by looking at the percent of patients taking any DM medication or by the number of DM medication class, being unable to look at dosage change or changes in medication for an individual patient was a limitation of their study. By analyzing each individual patient and examining both changes in the number of DM medication and the dosage, we find that the change of HbA1c was not due to an increase in oral hypoglycemic or insulin treatment. The findings imply that the change in HbA1c was most likely due to a change in host insulin resistance due to HCV clearance. This is in line with a recent study showing that HCV clearance with DAA reverses insulin resistance [27] . Our finding, however, is contrary to what Chaudhury et al [28] described in their recent paper published in December of 2017. While their study showed no change in HbA1c with DAA therapy, only 17% of patients had diabetes and their average baseline HbA1c was 5.75%. A reduction in HbA1c in a non-diabetic patient is hard to achieve. Therefore, it is reasonable to suggest that if they only examined patients with T2DM with a baseline HbA1c ≥ 6.5% they would have found similar conclusions.
Our data is further corroborated by data showing that successful treatment with DAA is also associated with a decreased likelihood of requiring higher insulin doses for DM management. This is contrary to a paper by Stine et al [29] showing that a third of patients required an increase in their DM medication after DAA therapy. However, they only examined patients up to the time of SVR12. It is possible that if they examined data one year after SVR12 they would have had similar results. Our study also shows that changes in HbA1c did not vary between HCV genotype and DAA treatment regimen, implying that HCV clearance itself plays an important role in insulin resistance. Even though the baseline HbA1c was different in those who did achieve SVR12 compared to those that did not, our study shows that metabolic syndrome or its individual components Prior studies have demonstrated an association between HCV infection and host metabolism. It has been shown that the hepatitis C virus depends on host lipids for entry and replication in hepatocytes [30] [31] [32] . HCV infection, in return, leads to a disruption of host metabolism, which can result in insulin resistance, lipid dysregulation, and hepatic steatosis [33] . The data represented here are consistent with data during the pegylated-interferon era where SVR clearance was associated with decreased insulin resistance and improved beta-cell function [10, 15, 34, 35] . Kawaguchi et al [15] , for example, demonstrated a three-fold increase in insulin receptor substrate 1 and 2 expressed in hepatocytes in 29 biopsy-proven HCV infection who maintained SVR after pegylated-interferon therapy. They also demonstrated a correlation between serum ferritin and homeostatic model assessment (HOMA) of β-cell function. Their data supports prior data that shows hepatic iron-induced oxidative stress may be related to insulin resistance [36] . Knobler et al [11] proposed an alternative mechanism in which HCV infection may mediate diabetes. In a comparison of 23 patients with DM and HCV to 28 patients with HCV alone, they showed that serum TNF-α levels were more prominent in those with concurrent DM. This is similar to prior data that shows that TNF-α signaling may be related to obesity and insulin resistance, thus suggesting a role of inflammation in creating a "diabetogenic" state [37] . During the era of pegylated-interferon, Bressler et al [14] showed that obesity was an independent risk factor for reduced SVR12. Because pegylatedinterferon is primarily taken up in the lymphatic system and because obese patients have poor lymphatic circulation, they proposed that the difference they described was due to dissimilar pharmacokinetic properties of obese and non-obese patients. While that may have been true for pegylated-interferon, our study shows that obesity, HTN, T2DM, or HLD does not significantly affect SVR12 rates of patients on DAA therapy. Unsurprisingly, SVR12 rates were reduced in patients with an elevated Fib-4 score, in patients with genotype 3, and in patients treated with suboptimal regimens such as sofosbuvir/ribavirin or sofosbuvir/ simeprevir. This is similar to prior studies showing reduced SVR12 in similar treated groups [38] [39] [40] . We further hypothesized that patients who were more ill were more likely to be treated for a longer duration thus explaining the discrepancy between SVR rates and treatment duration. While this study demonstrates the interplay between host metabolisms with HCV infection, there are certain limitations. The study implies that HCV clearance is associated with a reduction in insulin resistance, however, we were unable to measure insulin resistance directly before and after treatment. With primary care providers preferentially using HbA1c over fasting blood glucose, we were unable to use HOMA-IR (insulin resistance), HOMA-β (β-cell function), or other indices of insulin resistance. Nonetheless, HbA1c is a well-accepted and commonly utilized method to evaluate for insulin sensitivity, and we feel that using HbA1c as an outcome is consistent with clinical diagnosis, management, and prior studies [18, 20] . Second, September 27, 2018|Volume 10|Issue 9|
our study was a single center study conducted in the VA. VA patients are predominantly male and have different socioeconomic factors that may affect health as compared to the general population. Nonetheless, GLAVA is one of the largest VA medical center that includes an integrated network of 12 sites serving a racially and ethnically diverse population in Southern California.
In conclusion, this study of a diverse VA patient population demonstrates that HCV clearance with DAAs is associated with a clinically significant decrease in HbA1c. This change was consistent across all genotypes and treatment regimens. The change in HbA1c was independent of changes in BMI and DM medication requirements and so may represent a decrease in host insulin resistance or increased insulin sensitivity. This study substantiates similar studies during the pegylated-interferon era by showing that HCV clearance irrespective of treatment regimen and genotype leads to improved DM outcomes. However, unlike prior studies during the period of pegylated-interferon, we show that HTN, HLD, T2DM, obesity, and metabolic syndrome do not negatively affect SVR12 rates for DAA. Future prospective studies analyzing patient fasting blood glucose and serum insulin should be performed to validate these findings and to help elucidate the relationship between HCV, insulin sensitivity, and longerterm DM outcomes such as cardiovascular events.
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Research background
Hepatitis C virus (HCV) infection is a major worldwide health problem. There are increasing reports indicating an association between HCV and type 2 diabetes mellitus (T2DM). Individuals with HCV are more likely to have risk factors to develop T2DM and patients with T2DM have at least a 2-fold greater risk of developing HCV infection than the general population. Previously standard therapy for HCV required the use of pegylated interferon-α (P-IFN) and ribavirin. However, these regimens had low sustained virologic response (SVR) rates and were poorly tolerated. During the era of P-IFN therapy, several studies showed that the presence of obesity and/or steatosis led to a reduction of SVR rate in HCV patients. In patients with diabetes and HCV who were treated with IFN-based therapies, HCV clearance was associated with improved insulin resistance and beta cell function.
Research motivation
In 2013 and 2014, approval of newer direct acting antiviral agents (DAA) created IFN-free regimens with SVR rates greater than 90%, radically changing HCV treatment. Due to the novelty of DAA regimen, research is being actively pursued in a variety of patient populations.
Research ojectives
We aim to determine if successful treatment with DAA is associated with improvements in hemoglobin A1c (HbA1c) and if the presence of T2DM or metabolic syndrome affects SVR rates. 
Research methods
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We performed a retrospective analysis of all HCV patients at the VA Greater Los Angeles Healthcare System treated with DAA therapy between 2014-2016. Separate multivariable logistic regression was performed to determine predictors of HbA1c decrease ≥ 0.5 after DAA treatment and predictors of SVR 12-wk post treatment (SVR12). Patients with HCV were also included if they had diabetic medications on their medication list during the study period. Patients were excluded from the cohort if they did not have SVR12 data or a HbA1c one year after completion of DAA therapy.
Research results
A total of 1068 patients were treated with DAA therapy between 2014-2016. The presence of T2DM or metabolic syndrome did not adversely affect SVR12. 106 patients had both HCV and T2DM. Within that cohort, patients who achieved SVR12 had lower mean HbA1c pre-treatment (7.35 vs 8.60, P = 0.02), and lower mean HbA1c post-treatment compared to non-responders (6.55 vs 8.61, P = 0.01). The mean reduction in HbA1c after treatment was greater for those who achieved SVR12 than for non-responders (0.79 vs 0.01, P = 0.03).
In adjusted models, patients that achieved SVR12 were more likely to have a HbA1c decrease of > 0.5 than those that did not achieve SVR12 (adjusted OR = 7.24, 95%CI: 1.22-42.94).
Research conclusions
In conclusion, this study of a diverse VA patient population demonstrates that HCV clearance with DAAs is associated with a clinically significant decrease in HbA1c. This change was consistent across all genotypes and treatment regimens. The change in HbA1c was independent of changes in BMI and DM medication requirements and so may represent a decrease in host insulin resistance or increased insulin sensitivity. This study substantiates similar studies during the pegylated-interferon era by showing that HCV clearance irrespective of treatment regimen and genotype leads to improved DM outcomes. However, unlike prior studies during the period of pegylatedinterferon, we show that hypertension, hyperlipidemia, T2DM, obesity, and metabolic syndrome do not negatively affect SVR12 rates for DAA.
Research perspectives
Future prospective studies analyzing patient fasting blood glucose and serum insulin should be performed to validate these findings and to help elucidate the relationship between HCV, insulin sensitivity, and longer-term DM outcomes such as cardiovascular events.
